BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Endothelial cell
,
Amniocentesis
,
Valproic acid
,
rs3825942
,
PTEN
,
Coagulation
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
hepatocyte growth factor binding
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Pericardium
Bladder
Adipose tissue subcutaneous
Joint synovium
Synovial membrane
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Disorder of nervous system
Tobacco use and exposure (clinical finding)
Anal penetration by penis
Hepatocellular dysplasia
Musculoskeletal fibromatosis
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Inhba protein, mouse
Anti-Mullerian Hormone
cumene
vaccinia-CEA vaccine
Vasopressin (USP)
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
CCAR1
EZR
INHA
HHEX
TFE3
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Rhabdomyosarcoma cells overexpressing UNX1, RP58 (ZNF238) and miR-206
OMIM - Epilepsy disorders
L1000 CMAP - Adipose MSC ASC52telo cells with shRNA-mediated gene knockdown
OMIM - Congenital disorder
OMIM - Disorder of brain
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for hepatocyte growth factor binding
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (ME…
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
MP0250 DARPinĀ® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ